Latest Headlines

  1. Sapio Sciences Partners With The Wellcome Sanger Institute On Digital Laboratory Transformation 12/12/2025

    Sapio Sciences, the science-aware AI lab informatics platform, today announced that the Wellcome Sanger Institute has selected the Sapio Informatics Platform as its central LIMS to underpin the Institute’s ambitious lab transformation program.

  2. DNAe Unveils Early Access Program For LiDia SEQ™: Hospital Teams Invited To Trial DNAe's Flagship Tests And Preview DNAe's Innovative NGS Diagnostic Platform 12/11/2025

    DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical partners an exclusive pre-launch preview of the results generated by the company's world-first tests* – including the BSI/AMR Test targeting bloodstream infections and antimicrobial resistance – and the opportunity to later participate in pilot placements of DNAe's breakthrough Next Generation Sequencing (NGS)-based diagnostic system – LiDia-SEQ™.

  3. Microbix Launches New Products To Support H3N2 Flu Testing 12/10/2025

    Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QAPs™ quality assessment products and availability of QUANTDx™ reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “Flu”).

  4. Roche Launches New PCR Test To Help Improve Diagnostic Accuracy For Women Affected By Vaginitis In Countries Following The CE Mark 12/9/2025

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media proprietary tube.

  5. Korea University Researchers Develop Ultrasensitive Method To Detect Low-Frequency Cancer Mutations 12/9/2025

    MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero off-target activity.

  6. Yenos Analytical Launches The Yenos Test, First-Of-Its-Kind Multi-Cancer Early Detection Urine Test 12/9/2025

    Yenos Analytical LLC, a leader in cancer diagnostics using microRNA quantification and nanopore-array detection, today announced the launch of the Yenos cancer test, a new multi-cancer early detection (MCED) urine test that is now available as a laboratory-developed test (LDT) in the United States.

  7. Guardant Health And Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service In Italy 12/9/2025

    Guardant Health, Inc., a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy.

  8. Freenome And Perceptive Capital Solutions Corp Announce Business Combination Agreement To Create A Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection Through An AI/ML-Enabled Multiomics Platform 12/5/2025

    Freenome Holdings, Inc., an early cancer detection company developing blood-based screening tests, and Perceptive Capital Solutions Corp (Nasdaq: PCSC), a special purpose acquisition company (SPAC) sponsored by an affiliate of Perceptive Advisors, today announced that they have entered into a definitive business combination agreement.

  9. BD Launches New Cell Analyzer Configurations To Bring Cutting-Edge Capabilities To Labs Of All Sizes 12/5/2025

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.

  10. Natera Acquires Foresight Diagnostics 12/5/2025

    Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight.